News Preview
Dr Reddy's bets on generic semaglutide, biosimilars
Dr Reddy's domestic formulations business grew in the September quarter, with the company anticipating future growth from the relaunch of generic semaglutide and the US launch of abatacept biosimilar. The company aims to sell millions of pens for semaglutide and strengthen its biosimilars portfolio.
Want to stay up to date with the world events at sea or at home?
Explore Navvyx News - the best News app for seafarers.